Brief: Medicenna Presents Promising Clinical Data From Phase 2B Recurrent Glioblastoma Trial Of MDNA55

Medicenna Therapeutics

07/02/2019 12:05

Feb 7 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA PRESENTS PROMISING CLINICAL DATA FROM PHASE 2B
RECURRENT GLIOBLASTOMA TRIAL OF MDNA55
    * MEDICENNA THERAPEUTICS CORP - "STRONG INTERIM SURVIVAL
TREND
(15.2 VERSUS 8.5 MONTHS) EMERGING IN IL4R POSITIVE PATIENTS"
    * MEDICENNA THERAPEUTICS - ENROLMENT IN SECOND HALF OF STUDY
INCORPORATING A HIGHER DOSE OF MDNA55 IS EXPECTED TO BE
COMPLETED IN NEXT COUPLE OF MONTHS
    * MEDICENNA THERAPEUTICS CORP - TOP-LINE RESULTS FROM STUDY
EXPECTED IN MID-2019.

Source text for Eikon:  ID:nCNWsDkQLa 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))